Wedgewood Pharmacy is closely monitoring KV Pharmaceuticals’ introduction of Makena® (17 Alpha-Hydroxyprogesterone Caproate or 17P), which will have an impact on the cost and availability of the medication to women who are at risk of giving birth prematurely. As compounding pharmacy specialists, we, like other compounding pharmacies across the nation, have provided physicians and their patients with the compounded version of 17P for many years. Because Makena is priced higher than the cost of compounded 17P, we share the concerns of our colleagues, medical professionals and news media that this price increase may cause women in need to go untreated. On this page, we will provide useful information including communications from government officials and medical societies to the manufacturer and to the FDA, as well as news and opinion from respected sources.
Talk to your doctor about compounded 17 alpha hydroxyprogesterone